Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Array BioPharma, Pierre Fabre In Oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Array BioPharma, Pierre Fabre In Oncology Alliance

To develop Array's late-stage products, binimetinib and encorafenib

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Array BioPharma Inc. and Pierre Fabre have entered a collaboration to globally develop and commercialize Array’s late-stage oncology products, binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, are currently in Phase III trials for melanoma and ovarian cancer. The agreement is subject to European Commission review and approval.
 
Array will receive $30 million upfront and retains exclusive commercialization rights for binimetinib and encorafenib in the U.S., Canada, Japan, Korea and Israel. Pierre Fabre will have exclusive rights to both products in all other countries, including Europe, Asia and Latin America. Array is eligible to receive $425 million based on development and commercialization milestones, as well as royalties. The companies will share future development costs on a 60:40 basis (Array:Pierre Fabre) with initial funding committed for new clinical trials in colorectal cancer and melanoma. All ongoing binimetinib and encorafenib trials remain substantially funded through completion by Novartis.
  
“In Pierre Fabre we selected a partner with a European and emerging market focus in oncology to develop and commercialize binimetinib and encorafenib in these geographies,” said Ron Squarer, chief executive officer, Array BioPharma. “With Phase 3 trials approaching data readouts, and over 30 additional Phase 1/2 trials underway, we are confident that binimetinib and encorafenib are well positioned for near-term regulatory submissions and significant commercial value.”
 
“Pierre Fabre is strongly committed to develop and commercialize oncology products,” said Frederic Duchesne, chief executive officer, Pierre Fabre Pharmaceuticals. “This partnership with Array is aligned with our growth strategy in Pharmaceuticals, our geographic footprint, and our corporate mission to bring to the market novel oncology products which address unmet patient needs. Binimetinib and encorafenib will fit perfectly with our broad expertise in oncology and dermatology, and will strengthen our current portfolio and international presence.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics